Published on: 10 October 2017
Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study
Published on: 2 October 2017
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
Published on: 29 September 2017
Published on: 20 September 2017
Aims and scope
Hereditary Cancer in Clinical Practice is an open access journal that publishes articles of interest for the cancer genetics community and serves as a discussion forum for the development appropriate healthcare strategies.
Cancergenetics encompasses a wide variety of disciplines and knowledge in the field is rapidly growing, especially as the amount of information linking genetic differences to inherited cancer predispositions continues expanding. With the increased knowledge of genetic variability and how this relates to cancer risk there is a growing demand not only to disseminate this information into clinical practice but also to enable competent debate concerning how such information is managed and what it implies for patient care.
Topics covered by the journal include but are not limited to:
- Original research articles on any aspect of inherited predispositions to cancer.
- Reviews of inherited cancer predispositions.
- Application of molecular and cytogenetic analysis to clinical decision making.
- Clinical aspects of the management of hereditary cancers.
- Genetic counselling issues associated with cancer genetics.
- The role of registries in improving health care of patients with an inherited predisposition to cancer.
Meet the Editors-in-Chief
Jan Lubinski is a Professor of Medicine and Head of the International Hereditary Cancer Center (organized in 1992) of Pomeranian Medical University in Szczecin, Poland. The center conducted the first world-wide population screening for cancer family syndromes in a 1.7 million region of West-Pomerania, Poland in 2000-2001. It has a network of outpatient clinics covering almost the entire country as well as a cancer bio-bank with biological samples and clinical data from 250,000 cancer cases and appropriate controls, which includes registries of thousands of mutation carriers.
Rodney J Scott graduated from the University of Western Australia, Australia with a PhD in cellular biology and subsequently worked in the Department of Pathology and Laboratory Medicine at the University of Texas in Houston and then at the Centre for Teaching and Learning at the University of Basel, Switzerland. Since 1999 Prof. Scott has been a visiting Professor at the International Hereditary Cancer Center in Szczecin, Poland and more recently has been appointed as a adjunct Professor at the Universiti Kebangsaan Malaysia.